An Open Label, Multi-Center Study to Investigate the Safety of Cannabinoid (GWP42003-P) in Children With Medication Resistant Epilepsy

Trial Profile

An Open Label, Multi-Center Study to Investigate the Safety of Cannabinoid (GWP42003-P) in Children With Medication Resistant Epilepsy

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Expanded access; Therapeutic Use
  • Acronyms CBD
  • Most Recent Events

    • 04 May 2015 New source identified and integrated (ClinicalTrials.gov record : NCT02397863)
    • 22 Apr 2015 Data from 137 patients in this expanded access program were presented a the American Academy of Neurology Annual Meeting 2015, according to a GW Pharmaceuticals media release.
    • 22 Apr 2015 A GW Pharmaceuticals media release announced physician reports in 137 patients in this expanded access program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top